Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. The company offers men's health products, including vacuum erection devices, penile injections, PreBoost, VenoSeal, and urinary tract infection tests for the treatment of erectile dysfunction. Petros Pharmaceuticals, Inc. is based in New York, New York. more
Time Frame | PTPI | Sector | S&P500 |
---|---|---|---|
1-Week Return | 39.28% | -3.39% | 0.2% |
1-Month Return | 90.48% | -1.92% | 2.72% |
3-Month Return | 30.21% | -10.54% | 7.31% |
6-Month Return | 19.05% | -4.47% | 10.44% |
1-Year Return | -61.24% | 4.06% | 27.53% |
3-Year Return | -98.43% | 0.94% | 30.88% |
5-Year Return | -98.75% | 36.67% | 89.21% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 15.58M | 9.56M | 7.81M | 5.99M | 5.82M | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":61.37,"profit":true},{"date":"2021-12-31","value":50.15,"profit":true},{"date":"2022-12-31","value":38.47,"profit":true},{"date":"2023-12-31","value":37.38,"profit":true}] |
Cost of Revenue | 7.43M | 4.05M | 1.60M | 2.29M | 1.63M | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":54.48,"profit":true},{"date":"2021-12-31","value":21.54,"profit":true},{"date":"2022-12-31","value":30.83,"profit":true},{"date":"2023-12-31","value":21.96,"profit":true}] |
Gross Profit | 8.15M | 5.51M | 6.21M | 3.70M | 4.19M | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":67.64,"profit":true},{"date":"2021-12-31","value":76.22,"profit":true},{"date":"2022-12-31","value":45.43,"profit":true},{"date":"2023-12-31","value":51.43,"profit":true}] |
Gross Margin | 52.32% | 57.67% | 79.52% | 61.79% | 71.98% | [{"date":"2019-12-31","value":65.79,"profit":true},{"date":"2020-12-31","value":72.52,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":77.7,"profit":true},{"date":"2023-12-31","value":90.52,"profit":true}] |
Operating Expenses | 25.02M | 22.80M | 24.26M | 19.55M | 17.81M | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":91.11,"profit":true},{"date":"2021-12-31","value":96.97,"profit":true},{"date":"2022-12-31","value":78.14,"profit":true},{"date":"2023-12-31","value":71.18,"profit":true}] |
Operating Income | (16.87M) | (17.28M) | (18.05M) | (15.85M) | (13.62M) | [{"date":"2019-12-31","value":-1686827500,"profit":false},{"date":"2020-12-31","value":-1728203900,"profit":false},{"date":"2021-12-31","value":-1804801600,"profit":false},{"date":"2022-12-31","value":-1584569000,"profit":false},{"date":"2023-12-31","value":-1361736400,"profit":false}] |
Total Non-Operating Income/Expense | (30.13M) | (7.78M) | 8.69M | (703.65K) | 5.20M | [{"date":"2019-12-31","value":-346.66,"profit":false},{"date":"2020-12-31","value":-89.52,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-8.09,"profit":false},{"date":"2023-12-31","value":59.83,"profit":true}] |
Pre-Tax Income | (33.16M) | (22.01M) | (8.99M) | (20.04M) | (8.16M) | [{"date":"2019-12-31","value":-3315716600,"profit":false},{"date":"2020-12-31","value":-2201291800,"profit":false},{"date":"2021-12-31","value":-898667600,"profit":false},{"date":"2022-12-31","value":-2003757300,"profit":false},{"date":"2023-12-31","value":-816318800,"profit":false}] |
Income Taxes | (645.87K) | (1.43M) | 368.66K | 7.00M | 5.65B | [{"date":"2019-12-31","value":-0.01,"profit":false},{"date":"2020-12-31","value":-0.03,"profit":false},{"date":"2021-12-31","value":0.01,"profit":true},{"date":"2022-12-31","value":0.12,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Income After Taxes | (32.51M) | (20.59M) | (9.36M) | (27.04M) | (5.66B) | [{"date":"2019-12-31","value":-3251130000,"profit":false},{"date":"2020-12-31","value":-2058592500,"profit":false},{"date":"2021-12-31","value":-935533600,"profit":false},{"date":"2022-12-31","value":-2703757300,"profit":false},{"date":"2023-12-31","value":-565937418800,"profit":false}] |
Income From Continuous Operations | (32.51M) | (20.59M) | (8.99M) | (20.04M) | (12.70M) | [{"date":"2019-12-31","value":-3251130000,"profit":false},{"date":"2020-12-31","value":-2058592500,"profit":false},{"date":"2021-12-31","value":-898667600,"profit":false},{"date":"2022-12-31","value":-2003757300,"profit":false},{"date":"2023-12-31","value":-1270269800,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (32.51M) | (20.59M) | (9.36M) | (27.04M) | (8.16M) | [{"date":"2019-12-31","value":-3251130000,"profit":false},{"date":"2020-12-31","value":-2058592500,"profit":false},{"date":"2021-12-31","value":-935533600,"profit":false},{"date":"2022-12-31","value":-2703757300,"profit":false},{"date":"2023-12-31","value":-816318800,"profit":false}] |
EPS (Diluted) | (17.80) | (8.11) | (0.91) | (2.80) | (6.34) | [{"date":"2019-12-31","value":-1780.43,"profit":false},{"date":"2020-12-31","value":-811.09,"profit":false},{"date":"2021-12-31","value":-91,"profit":false},{"date":"2022-12-31","value":-280,"profit":false},{"date":"2023-12-31","value":-634.22,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
PTPI | |
---|---|
Cash Ratio | 0.31 |
Current Ratio | 0.85 |
Quick Ratio | 0.74 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
PTPI | |
---|---|
ROA (LTM) | -30.61% |
ROE (LTM) | -63.77% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
PTPI | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.85 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.15 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
PTPI | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.65 |
P/B | 0.86 |
Price/FCF | NM |
EV/R | 1.50 |
EV/Ebitda | NM |
Petros Pharmaceuticals Inc (PTPI) share price today is $0.369
Yes, Indians can buy shares of Petros Pharmaceuticals Inc (PTPI) on Vested. To buy Petros Pharmaceuticals Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in PTPI stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Petros Pharmaceuticals Inc (PTPI) via the Vested app. You can start investing in Petros Pharmaceuticals Inc (PTPI) with a minimum investment of $1.
You can invest in shares of Petros Pharmaceuticals Inc (PTPI) via Vested in three simple steps:
The 52-week high price of Petros Pharmaceuticals Inc (PTPI) is $2.27. The 52-week low price of Petros Pharmaceuticals Inc (PTPI) is $0.22.
The price-to-earnings (P/E) ratio of Petros Pharmaceuticals Inc (PTPI) is
The price-to-book (P/B) ratio of Petros Pharmaceuticals Inc (PTPI) is 0.86
The dividend yield of Petros Pharmaceuticals Inc (PTPI) is 0.00%
The market capitalization of Petros Pharmaceuticals Inc (PTPI) is $2.67M
The stock symbol (or ticker) of Petros Pharmaceuticals Inc is PTPI